Viewing Study NCT06393751

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:42 PM
Ignite Modification Date: 2026-06-17 @ 1:01 AM
Study NCT ID: NCT06393751
Status: WITHDRAWN
Last Update Posted: 2025-06-03
First Post: 2024-04-30
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer
Sponsor: National Cancer Institute (NCI)
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Platinum-Refractory Fallopian Tube Carcinoma View
None Platinum-Refractory Ovarian Carcinoma View
None Platinum-Refractory Primary Peritoneal Carcinoma View
None Recurrent Fallopian Tube Adenocarcinoma View
None Recurrent Fallopian Tube Carcinosarcoma View
None Recurrent Fallopian Tube Clear Cell Adenocarcinoma View
None Recurrent Fallopian Tube High Grade Serous Adenocarcinoma View
None Recurrent Fallopian Tube Undifferentiated Carcinoma View
None Recurrent High Grade Endometrioid Adenocarcinoma View
None Recurrent Ovarian Adenocarcinoma View
None Recurrent Ovarian Carcinosarcoma View
None Recurrent Ovarian Clear Cell Adenocarcinoma View
None Recurrent Ovarian High Grade Serous Adenocarcinoma View
None Recurrent Ovarian Seromucinous Carcinoma View
None Recurrent Ovarian Undifferentiated Carcinoma View
None Recurrent Platinum-Resistant Fallopian Tube Carcinoma View
None Recurrent Platinum-Resistant Ovarian Carcinoma View
None Recurrent Platinum-Resistant Primary Peritoneal Carcinoma View
None Recurrent Primary Peritoneal Adenocarcinoma View
None Recurrent Primary Peritoneal Carcinosarcoma View
None Recurrent Primary Peritoneal Clear Cell Adenocarcinoma View
None Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma View
None Recurrent Primary Peritoneal Undifferentiated Carcinoma View
Keywords: